Skip to main content
News

MIPS 25th Anniversary Profile: MedImmune–characterization of Synagis® – Mtech Blog

By November 9, 2012No Comments
medimmune-synagis

medimmune-synagis

Gaithersburg-based MedImmune is the global biologics arm of AstraZeneca PLC, with approximately 3,500 employees worldwide.

MedImmune’s Synagis® product is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.

Synagis® prevents a serious lower respiratory tract disease caused by the respiratory synctial virus (RSV), prominent in the Northern Hemisphere during the winter months. RSV is the most common respiratory infection for infants and children. Approximately 50 percent of all infants are infected with RSV during their first year of life; nearly all children have been infected at least once by the time they reach their second birthday.

{iframe}http://mtechumd.wordpress.com/2012/11/07/mips-25th-anniversary-profile-medimmune-characterization-of-synagis/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.